Trials / Terminated
TerminatedNCT03355300
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures
A Multicenter, Open-Label, Flexible Dose Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Radius Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 3 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in pediatric participants with treatment-resistant childhood absence seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cannabidiol Oral Solution | An oral solution containing pharmaceutical grade cannabidiol (nonplant-based). |
Timeline
- Start date
- 2018-02-20
- Primary completion
- 2019-06-24
- Completion
- 2019-06-28
- First posted
- 2017-11-28
- Last updated
- 2023-06-18
- Results posted
- 2023-06-18
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03355300. Inclusion in this directory is not an endorsement.